The MMRF would like to recognize Legend Biotech as a Select Event Sponsor of the MMRF Walk/Run: Atlanta, San Francisco, and Twin Cities. “We at Legend Biotech are honored to expand our sponsorship of the Team for Cures and join the MMRF in cities across the country. Through our active involvement in the Walk/Run program, we are committed to amplifying awareness of this vital cause.” - Legend Biotech. Register FREE today for an MMRF Walk/Run https://bit.ly/3tTJBFq!
Multiple Myeloma Research Foundation - MMRF
Non-profit Organizations
Norwalk, Connecticut 14,259 followers
Accelerating a smarter, faster, cure for mutiple myeloma.
About us
We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients.
- Website
-
http://themmrf.org
External link for Multiple Myeloma Research Foundation - MMRF
- Industry
- Non-profit Organizations
- Company size
- 51-200 employees
- Headquarters
- Norwalk, Connecticut
- Type
- Nonprofit
- Founded
- 1998
Locations
-
Primary
383 Main Avenue
5th Floor
Norwalk, Connecticut 06851, US
Employees at Multiple Myeloma Research Foundation - MMRF
-
Pam Lewis
Leader in Fundraising, Patient Advocacy and Programming. Catalyst and Pied Piper.
-
Christopher Williams
-
Adriana Davis
Producer/Editor/Voice-Over Artist, Director
-
Lori Tauber Marcus
Experienced Board Director, Chair, Compensation Committee, Nominating Governance Committee, Audit Committee, Board Development Committee, Public…
Updates
-
Andrew has kept a positive outlook and is self-motivating. He feels that his #multiplemyeloma journey has made him a better person in that he is more compassionate and understanding. No matter your disease state you are not alone ❤️. Our mentors have insights and information that can benefit both #myeloma patients and their caregivers. To schedule time with Andrew or any of our other mentors, visit: https://ow.ly/BYUS50SNhAQ
-
-
Healthcare professionals: Data from #ASCO2024 and #EHA2024 indicate promising outcomes associated with newer #myeloma treatment approaches, including CD38-targeting monoclonal antibodies, CAR T-cell therapy, bispecific antibodies, and antibody–drug conjugates. Read here: https://lnkd.in/eubAB-bM
-
The MMRF would like to recognize Arcellx as a Leading Event Sponsor of the MMRF Walk/Run: San Francisco. “It’s an honor to support the MMRF Foundation in its tireless efforts to help patients and their families impacted by multiple myeloma. Our team at Arcellx looks forward to joining the Walk/Run events on August 24th continuing to raise awareness about this devastating disease.” - Christopher Heery, Chief Medical Officer.
-
-
We're thrilled to announce that the Myeloma Investment Fund (MIF) has invested in Nammi Therapeutics, Inc., supporting their innovative immunotherapy, QXL138AM, aimed at treating multiple myeloma and other tumors. This investment reflects our tireless commitment to fostering innovation and supporting the development of therapies that can make a real impact on the lives of those affected by this disease. https://ow.ly/MyZY50SSrCg
Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM - MMRF
https://themmrf.org
-
This month, during National Make-a-Will Month, strengthen your legacy and build a future of hope & progress for our loved ones and the #myeloma community. With our partner, FreeWill, you can create a will that reflects your wishes easily at no cost. By including an optional gift to the MMRF, you can extend your impact on the work we do to: 🔬 Accelerate the development of novel therapies 💉 Drive optimal and more personalized treatment approaches 📄 Provide critical information and resources for the best possible outcomes Create your will today: https://ow.ly/22Y050SNuTV
-
-
Healthcare providers: In this NEW educational activity familiarize yourself with strategies for preventing and managing potentially life-threatening adverse events associated with bispecific antibody therapy, including cytokine release syndrome (CRS), neurotoxicity, and infection. Start this activity today: https://ow.ly/HpK350SMIWa #Myeloma #MultipleMyeloma #HealthcareEducation #BispecificAntibodies
Managing Bispecific Antibody–Associated AEs in Myeloma | myCME
mycme.com
-
Immunotherapies are powerful myeloma treatments that can provide durable remissions, but side effects are common. In our newest Myeloma Matters podcast episode, you’ll learn how to recognize and get through the main side effects of myeloma immunotherapy. Listen here: https://ow.ly/bTFe50SMITu #mmsm
Myeloma Matters Podcast | Immunotherapy Side Effects
https://www.youtube.com/
-
🎉 Congratulations to Dr. Hearn Cho on your well-deserved promotion to Clinical Professor of Medicine (Hematology and Medical Oncology) at Icahn School of Medicine at Mount Sinai!
-
-
On 7/30 the U.S. FDA announced approval of Johnson & Johnson Innovative Medicine’s Darzalex FasPro, as part of a 4-drug combination (including bortezomib, lenalidomide and dexamethasone) for newly diagnosed patients. #myeloma https://lnkd.in/e3wxqgXt Learn more about the Darzalex FasPro study. https://lnkd.in/e8AR67sJ
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible
jnj.com